Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Current Liabilities: 2011-2024

Historic Total Current Liabilities for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to $17.9 million.

  • Niagen Bioscience's Total Current Liabilities rose 28.32% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year increase of 28.32%. This contributed to the annual value of $17.9 million for FY2024, which is 12.97% down from last year.
  • Niagen Bioscience's Total Current Liabilities amounted to $17.9 million in FY2024, which was down 12.97% from $20.6 million recorded in FY2023.
  • In the past 5 years, Niagen Bioscience's Total Current Liabilities registered a high of $20.6 million during FY2023, and its lowest value of $16.5 million during FY2020.
  • In the last 3 years, Niagen Bioscience's Total Current Liabilities had a median value of $17.9 million in 2024 and averaged $18.8 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first climbed by 15.41% in 2023, then decreased by 12.97% in 2024.
  • Niagen Bioscience's Total Current Liabilities (Yearly) stood at $16.5 million in 2020, then rose by 6.90% to $17.6 million in 2021, then increased by 1.45% to $17.9 million in 2022, then climbed by 15.41% to $20.6 million in 2023, then decreased by 12.97% to $17.9 million in 2024.